MFA Financial Valuation
Is M4ZA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of M4ZA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate M4ZA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate M4ZA's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for M4ZA?
Other financial metrics that can be useful for relative valuation.
| What is M4ZA's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$1.10b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | 0.5x |
Price to Earnings Ratio vs Peers
How does M4ZA's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 29.5x | ||
GLJ Grenke | 12.1x | 18.2% | €1.0b |
FTK flatexDEGIRO | 13.8x | 12.5% | €1.3b |
HYQ Hypoport | 82.8x | 31.8% | €1.7b |
PBB Deutsche Pfandbriefbank | 9.1x | 28.2% | €621.8m |
M4ZA MFA Financial | 23.2x | 43.9% | €1.1b |
Price-To-Earnings vs Peers: M4ZA is good value based on its Price-To-Earnings Ratio (23.2x) compared to the peer average (29.5x).
Price to Earnings Ratio vs Industry
How does M4ZA's PE Ratio compare vs other companies in the Global Mortgage REITs Industry?
Price-To-Earnings vs Industry: M4ZA is expensive based on its Price-To-Earnings Ratio (23.2x) compared to the Global Mortgage REITs industry average (11.8x).
Price to Earnings Ratio vs Fair Ratio
What is M4ZA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 23.2x |
| Fair PE Ratio | 28.1x |
Price-To-Earnings vs Fair Ratio: M4ZA is good value based on its Price-To-Earnings Ratio (23.2x) compared to the estimated Fair Price-To-Earnings Ratio (28.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €10.00 | €14.45 +44.5% | 44.9% | €28.89 | €10.72 | n/a | 6 |
| Apr ’25 | €10.36 | €14.38 +38.8% | 44.3% | €28.61 | €11.07 | n/a | 6 |
| Mar ’25 | €10.32 | €14.38 +39.3% | 44.3% | €28.61 | €11.07 | n/a | 6 |
| Feb ’25 | €10.34 | €13.65 +32.0% | 44.5% | €28.49 | €10.11 | n/a | 7 |
| Jan ’25 | €10.16 | €13.53 +33.1% | 45.3% | €28.50 | €10.11 | n/a | 7 |
| Dec ’24 | €10.14 | €13.75 +35.6% | 47.6% | €28.33 | €10.05 | n/a | 6 |
| Nov ’24 | €8.64 | €14.45 +67.2% | 46.1% | €29.29 | €10.39 | n/a | 6 |
| Oct ’24 | €9.05 | €14.55 +60.7% | 44.9% | €29.01 | €10.29 | n/a | 6 |
| Sep ’24 | €10.10 | €14.24 +40.9% | 44.4% | €28.24 | €10.02 | n/a | 6 |
| Aug ’24 | €10.20 | €14.05 +37.7% | 44.4% | €27.87 | €9.89 | n/a | 6 |
| Jul ’24 | €10.28 | €14.41 +40.2% | 45.2% | €28.90 | €10.25 | n/a | 6 |
| Jun ’24 | €10.02 | €14.41 +43.8% | 45.2% | €28.90 | €10.25 | n/a | 6 |
| May ’24 | €9.50 | €13.88 +46.2% | 46.0% | €28.07 | €9.96 | n/a | 6 |
| Apr ’24 | €8.95 | €14.26 +59.4% | 45.0% | €28.53 | €10.12 | €10.36 | 6 |
| Mar ’24 | €9.80 | €14.26 +45.6% | 45.0% | €28.53 | €10.12 | €10.32 | 6 |
| Feb ’24 | €11.00 | €14.26 +29.7% | 45.0% | €28.53 | €10.12 | €10.34 | 6 |
| Jan ’24 | €9.13 | €14.43 +58.1% | 45.5% | €29.02 | €10.30 | €10.16 | 6 |
| Dec ’23 | €10.46 | €14.50 +38.6% | 47.8% | €29.80 | €9.61 | €10.14 | 6 |
| Nov ’23 | €9.92 | €15.25 +53.8% | 49.0% | €31.69 | €10.22 | €8.64 | 6 |
| Oct ’23 | €7.92 | €17.18 +117.0% | 34.9% | €30.51 | €13.04 | €9.05 | 6 |
| Sep ’23 | €10.56 | €17.18 +62.7% | 34.9% | €30.51 | €13.04 | €10.10 | 6 |
| Aug ’23 | €12.80 | €17.32 +35.3% | 34.6% | €30.46 | €12.53 | €10.20 | 6 |
| Jul ’23 | €10.67 | €18.45 +72.9% | 28.5% | €29.77 | €14.41 | €10.28 | 6 |
| Jun ’23 | €13.07 | €18.45 +41.2% | 26.4% | €29.03 | €14.05 | €10.02 | 6 |
| May ’23 | €13.49 | €19.27 +42.8% | 23.4% | €29.14 | €15.98 | €9.50 | 6 |
| Apr ’23 | €14.37 | €19.36 +34.7% | 19.7% | €27.49 | €15.96 | €8.95 | 6 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.